Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor Malignancies 1Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Advanced or Recurrent Solid Tumors 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × vadimezan × Clear all
NCT01240642 2020-12-09

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Novartis

Phase 1 Terminated
27 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01278758 2020-12-09

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Novartis

Phase 1 Terminated
7 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01278849 2020-12-09

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Novartis

Phase 1 Terminated
5 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01299701 2017-02-14

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Novartis

Phase 1 Terminated
7 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡